Individualizing anaemia treatment: A discussion of case histories

Nephrology Dialysis Transplantation

Volumn 20, Issue SUPPL. 6, 2005, Pages

  Muirhead, Norman ^a,b  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b LONDON HEALTH SCIENCES CENTRE   (Canada)

Author keywords

Anaemia; Cardiovascular; Epoetin; Haematocrit; Haemoglobin; Pre dialysis; Target

Indexed keywords

AMLODIPINE; ANTIHYPERTENSIVE AGENT; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOMPERIDONE; DOXAZOSIN; FUROSEMIDE; GLIBENCLAMIDE; HEMOGLOBIN; HYDROCHLOROTHIAZIDE; INSULIN; IRON; METFORMIN; METOPROLOL; ORAL ANTIDIABETIC AGENT; PRAVASTATIN; RAMIPRIL; RECOMBINANT ERYTHROPOIETIN; ANTIANEMIC AGENT;

ADULT; AGED; ANAMNESIS; ANEMIA; ANGINA PECTORIS; ARTICLE; CASE REPORT; CHRONIC GLOMERULONEPHRITIS; CHRONIC KIDNEY FAILURE; CLINICAL PROTOCOL; CONSULTATION; DRUG MEGADOSE; FEMALE; HEMODIALYSIS; HUMAN; HYPERTENSION; IRON DEFICIENCY; IRON THERAPY; ISCHEMIC HEART DISEASE; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT REFERRAL; PRIORITY JOURNAL; SYMPTOM; TREATMENT OUTCOME; BLOOD; DOSE RESPONSE; MIDDLE AGED; RENAL REPLACEMENT THERAPY;

AGED; ANEMIA; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; EPOETIN ALFA; FEMALE; HEMATINICS; HEMOGLOBINS; HUMANS; HYPERTENSION; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; RENAL DIALYSIS;

EID: 32944481639     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfh1094     Document Type: Article

References (30)

1. Locatelli F, Aljama P, Barany P et al. Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant 2004; 19 [Suppl 2]: Ii1-ii47
2. National Kidney Foundation. K/DOQI clinical practice guidelines for anemia of chronic kidney disease: Update 2000. Am J Kidney Dis 2001; 37 [Suppl 1]: S182-S238
3. Foley RN, Parfrey PS, Morgan J et al. Effect of hemoglobin levels in hemodialysis patients with asymptomatic cardiomyopathy. Kidney Int 2000; 58: 1325-1335
4. McMahon LP, Mason K, Skinner SL, Burge CM, Grigg LE, Becker GJ. Effects of normalization on quality of life and cardiovascular parameters in end-stage renal failure. Nephrol Dial Transplant 2000; 15: 1425-1430
5. Moreno F, Sanz-Guajardo D, López-Gómez JM, Jofre R, Valderrábano F. Increasing the hematocrit has a beneficial effect on quality of life and is safe in selected hemodialysis patients. J Am Soc Nephrol 2000; 11: 335-342
6. Besarab A, Bolton WK, Browne JK et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 1998; 339: 584-590
7. Hörl WH, Jacobs C, Macdougall IC et al. European Best Practice Guidelines 14-16: Inadequate response to epoetin. Nephrol Dial Transplant 2000; 15 [Suppl 4]: 43-50
8. Sunder-Plassman G, Spitzauer S, Hörl WH. The dilemma of evaluating iron status in dialysis patients - limitations of available diagnostic procedures. Nephrol Dial Transplant 1997; 12: 1575-1580
9. Cavill I. Erythropoiesis and iron. Best Pract Res Clin Haematol 2002; 15: 399-409
10. McMahon LP, McKenna MJ, Sangkabutra T et al. Physical performance and associated electrolyte changes after haemoglobin normalization: A comparative study in haemodialysis patients. Nephrol Dial Transplant 1999; 14: 1182-1187
11. Macdougall IC. The role of ACE inhibitors and angiotensin II receptor blockers in the response to epoetin. Nephrol Dial Transplant 1999; 14: 1836-1841
12. Eustace JA, Mellotte GJ, Keogn JA. Treatment of post-transplant erythrocytosis by angiotensin II type I receptor antagonists. Nephrol Dial Transplant 1996; 11: 2373-2374
13. Mrug M, Stopka T, Julian BA, Prchal JF, Prchal JT. Angiotensin II stimulates proliferation of normal early erythroid progenitors. J Clin Invest 1997; 100: 2310-2314
14. Azizi M, Rousseau A, Ezan E et al. Acute angiotensin-converting enzyme inhibition increases the plasma level of the natural stem cell regulator N-acetyl-seryl-aspartyl-lysyl-proline. J Clin Invest 1996; 97: 839-844
15. Morrone LF, Di Paolo S, Logoluso F et al. Interference of angiotensin-converting enzyme inhibitors on erythropoiesis in kidney transplant recipients: Role of growth factors and cytokines. Transplantation 1997; 64: 913-918
16. Constantinescu CS, Goodman DB, Ventura ES. Captopril and lisinopril suppress production of interleukin-12 by human peripheral blood mononuclear cells. Immunol Lett 1998; 62: 25-31
17. Silberberg JS, Barre PE, Prichard SS, Sinderman AD. Impact of left ventricular hypertrophy on survival in end-stage renal disease. Kidney Int 1989; 36: 286-290
18. Portolés J, Torralbo A, Martin P, Rodrigo J, Herrero JA, Barrientos A. Cardiovascular effects of recombinant human erythropoietin in predialysis patients. Am J Kidney Dis 1997; 29: 541-548
19. Hayashi T, Suzuki A, Shoji T et al. Cardiovascular effect of normalizing the hematocrit level during erythropoietin therapy in predialysis patients with chronic renal failure. Am J Kidney Dis 2000; 35: 250-256
20. Silverberg D. Outcomes of anaemia management in renal insufficiency and cardiac disease. Nephrol Dial Transplant 2003; 18 [Suppl 2]: Ii7-ii12
21. Foley RN, Parfrey PS, Harnett JD, Kent GM, Murray DC, Barre PE. The impact of anemia on cardiomyopathy, morbidity, and mortality in end-stage renal disease. Am J Kidney Dis 1996; 28: 53-61
22. Muirhead N. A rationale for an individualized haemoglobin target. Nephrol Dial Transplant 2002; 17 [Suppl 6]: 2-7
23. Macdougall IC. Should the hematocrit be normalized in dialysis and in pre-ESRD patients? Blood Purif 2001; 19: 157-167
24. Collins AJ, Li S, Ma JZ, Herzog C. Cardiovascular disease in end-stage renal disease patients. Am J Kidney Dis 2001; 38 [Suppl 1]: S26-S29
25. Foley RN, Parfrey PS, Harnett JD et al. Clinical and echocardiographic disease in patients starting end-stage renal disease therapy. Kidney Int 1995; 47: 186-192
26. Astor BC, Muntner P, Levin A, Eustace JA, Coresh J. Association of kidney function with anemia: The Third National Health and Nutrition Examination Survey (1988-1994). Arch Intern Med 2002; 162: 1401-1408
27. Collins AJ. Anaemia management prior to dialysis: Cardiovascular and cost-benefit observations. Nephrol Dial Transplant 2003; 18 [Suppl 2]: ii2-ii6
28. Xue JL, St Peter WL, Ebben JP, Everson SE, Collins AJ. Anemia treatment in the pre-ESRD period and associated mortality in elderly patients. Am J Kidney Dis 2002; 40: 1153-1161
29. Valderrábano F, Hörl WH, Macdougall IC, Rossert J, Rutkowski B, Wauters JP. PRE-dialysis survey on anaemia management. Nephrol Dial Transplant 2003; 18: 89-100
30. Macdougall IC. CREATE: New strategies for early anaemia management in renal insufficiency. Nephrol Dial Transplant 2003; 18 [Suppl 2]: ii13-ii16